ARTICLE | Clinical News
Revance's RT002 meets in pair of Phase III trials for frown lines
December 8, 2017 4:19 AM UTC
Revance Therapeutics Inc. (NASDAQ:RVNC) said a single injection of DaxibotulinumtoxinA for Injection (RT002) met the primary and all secondary endpoints in the Phase III SAKURA 1 and SAKURA 2 trials to treat moderate to severe glabellar lines, or frown lines between the eyebrows. Revance plans to submit a BLA to FDA for the candidate in 1H19.
Revance said that if approved, RT002 would be the first neuromodulator with a long-acting duration of 6 months. Marketed neuromodulators have shown a duration of activity of 3 to 4 months in treating glabellar lines, according to Revance. The injectable botulinum toxin type A uses Revance's TransMTS technology...
BCIQ Company Profiles